Get started

Financials · CNSY

Cerenome Inc. (CNSY) financials

For the twelve months ended Jun 30, 2026, Cerenome Inc. reported $4.20M of revenue and -$26.09M of net income.

Revenue, TTM
$4.20M
Revenue growth, YoY
-21.0%
Net income, TTM
-$26.09M
Net margin
-620.7%
Free cash flow, TTM
-$23.55M
Cash
$2.37M
P/S
1.03
Market cap
$4.3M
Annual revenue$5.21M
FY2016FY2025
Annual net income-$22.39M
FY2016FY2025
Annual free cash flow-$20.84M
FY2016FY2025

CNSY revenue and earnings growth

CNSY revenueQ2 2026$411.0K

Quarter YoY
-70.4%
QoQ
-60.0%
FY YoY
-10.5%
10Y CAGR
+0.7%

CNSY revenue was $411.0K in fiscal Q2 2026 (ended Jun 30, 2026), down 70.4% from a year earlier and down 60.0% from the prior quarter. For the full fiscal 2025 it was $5.21M, down 10.5% from fiscal 2024. Compound annual growth was +0.7% over 10 years.

CNSY net incomeQ2 2026-$9.01M

CNSY net income was -$9.01M in fiscal Q2 2026 (ended Jun 30, 2026), compared with $5.15M a year earlier. For the full fiscal 2025 it was -$22.39M, compared with -$12.98M in fiscal 2024.

CNSY EPSQ2 2026-$1.31

CNSY diluted EPS was -$1.31 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.16 a year earlier. For the full fiscal 2025 it was -$7.25.

CNSY free cash flowQ2 2026-$7.63M

CNSY free cash flow was -$7.63M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$5.80M a year earlier. For the full fiscal 2025 it was -$20.84M, compared with -$10.70M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$5.21M$5.82M$4.91M----$3.67M$2.69M$4.66M
Cost of revenue-------$1.15M$1.32M$2.71M
Gross profit-------$2.52M$146.0K$1.94M
Research and development$8.38M$10.58M$9.69M$9.70M$5.32M$2.70M$5.37M$5.52M$11.68M$16.20M
Selling, general and admin$12.13M$9.94M$8.54M$10.24M$6.85M$6.41M$5.29M$5.58M$7.59M$8.56M
Operating income-$15.30M-$14.70M-$13.32M-$19.71M-$12.49M-$9.58M-$3.66M-$8.76M-$20.68M-$19.71M
Interest expense$548.0K$179.0K$395.0K$711.0K$932.0K$1.11M$1.85M$1.92M$2.05M$2.59M
Pre-tax income-$22.39M-$12.98M--------
Income tax$0$0$0$0$0$0$0$0$0$0
Net income-$22.39M-$12.98M-$13.32M-$20.27M-$13.40M-$8.24M-$10.89M-$12.63M-$22.69M-$22.05M
EPS, basic-$7.25-$48.75-$106.00-$289.50-$416.25-$697.50-$3101.25-$32617.50-$154312.50-$240000.00
EPS, diluted-$7.25-$58.50-$106.00-$289.50-$416.25-$697.50-$3101.25-$32617.50-$154312.50-$240000.00
Diluted shares3.1M308,030.96125,63770,01432,237.82911,807.563,690.699463.603172.74692.218

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$4.26M$76.0K$8.55M$18.12M$18.40M$8.35M$17.55M$5.26M$9.55M$12.60M
Short-term investments$4.36M$3.53M--------
Receivables-----$0$1.17M$178.0K$145.0K$1.24M
Inventory------$107.0K$107.0K$3.18M$3.73M
Current assets$15.17M$5.26M$9.83M$21.82M$19.72M$9.18M$19.82M$9.65M$14.86M$18.75M
Goodwill$372.0K$372.0K$372.0K$372.0K$372.0K$372.0K$372.0K$372.0K$3.92M$3.92M
Total assets$16.32M$6.63M$11.39M$23.87M$21.98M$12.11M$23.23M$23.99M$31.61M$34.61M
Current liabilities$12.31M$15.55M$10.73M$11.85M$5.87M$8.54M$14.49M$17.56M$18.41M$12.50M
Short-term debt--$3.98M$1.61M$1.61M$6.33M$11.06M$14.20M$13.62M$6.63M
Long-term debt---$3.79M$5.00M---$0$11.01M
Total debt---$5.39M$6.61M$6.33M$11.06M$14.20M$13.62M$17.64M
Total liabilities$12.33M$15.58M$12.74M$17.42M$11.14M$9.07M$22.07M$18.77M$18.61M$23.62M
Shareholders' equity$4.00M-$8.95M-$1.35M$6.45M$10.84M$3.03M$1.16M$5.22M$13.00M$10.99M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$20.77M-$10.55M-$12.85M-$12.97M-$10.28M-$8.43M-$5.91M-$11.97M-$18.13M-$19.53M
Capital expenditures$67.0K$146.0K$160.0K---$67.0K$133.0K$295.0K$67.0K
Free cash flow-$20.84M-$10.70M-$13.01M----$5.97M-$12.11M-$18.42M-$19.60M
Investing cash flow-$854.0K-$4.11M-$160.0K-$759.0K-$82.0K-$493.0K$5.57M-$133.0K-$1.38M$64.0K
Financing cash flow$30.31M$6.19M$3.44M$13.45M$20.42M-$319.0K$12.63M$7.17M$16.82M$17.61M
Stock-based compensation$1.54M$550.0K$569.0K$606.0K$606.0K$247.0K$127.0K$355.0K$753.0K$1.08M
Depreciation and amortization$445.0K$872.0K$628.0K$619.0K$395.0K$366.0K$896.0K$2.00M$2.15M$1.18M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY-10.5%18.5%-----36.5%-42.2%-3.8%
Gross margin-------68.7%5.4%41.7%
Operating margin-293.5%-252.3%-271.1%-----238.7%-769.2%-423.2%
Net margin-429.4%-222.8%-271.0%-----344.2%-843.7%-473.5%
Free cash flow margin-399.8%-183.7%-264.8%-----329.8%-685.1%-421.0%
Return on equity-560.2%---314.6%-123.7%-271.9%-938.5%-241.8%-174.5%-200.7%
Return on assets-137.1%-195.7%-116.9%-84.9%-61.0%-68.1%-46.9%-52.7%-71.8%-63.7%
Current ratio1.230.340.921.843.361.071.370.550.811.50
Debt to equity---0.840.612.099.532.721.051.61

Source: XBRL data Cerenome Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-15, first reported May 10, 2016; 1-for-10, first reported Aug 14, 2018; 1-for-50, first reported Aug 15, 2019; 1-for-15, first reported Aug 14, 2023; 1-for-25, first reported May 15, 2026.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

CNSY peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
CNSY$4.20M-21.0%-$26.09M-620.7%$4.3M
SYK$26.30B+7.9%$3.62B13.8%$124.00B
MMM$25.25B+1.7%$3.54B14.0%$97.47B
BSX$21.07B+8.9%$3.50B16.6%$63.81B
BDX$23.25B+17.4%$941.00M4.0%$58.63B
MDLN$30.68B-$683.00M2.2%$53.55B
RMD$5.73B+9.0%$1.59B27.8%$33.16B
DXCM$5.10B+13.0%$991.00M19.4%$30.24B
WST$3.40B+12.6%$638.90M18.8%$28.78B

CNSY FAQ

7 questions
  • What is CNSY revenue?
    Cerenome Inc. (CNSY) reported $4.20M of revenue for the twelve months ended Jun 30, 2026. That is down 21.0% from the year before. Revenue for fiscal 2025 was $5.21M.
  • Is CNSY profitable?
    No. Cerenome Inc. reported a net loss of $26.09M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does CNSY have?
    Cerenome Inc. reported $2.37M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is CNSY revenue growing?
    Cerenome Inc.'s revenue changed -10.5% in fiscal 2025, to $5.21M. Its compound annual growth rate was +0.7% over 10 years.
  • What is CNSY free cash flow?
    Cerenome Inc. generated -$23.55M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$22.18M less capital expenditures.
  • When did CNSY last report financial results?
    The latest statements here come from Cerenome Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.
  • Where does this CNSY financial data come from?
    Quantisnow builds these statements from the structured XBRL data Cerenome Inc. files with the SEC. It is provided for information only and is not investment advice.